<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2213771699-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2213771699-430x241.jpg"/></p>
<p>拜玛林制药已达成最终协议，以 48 亿美元收购罕见疾病生物技术公司爱美医疗。图片来源：T. Schneider via ShutterStock.com。</p>
<p>拜玛林制药已同意收购罕见疾病生物技术公司爱美医疗，向其产品组合中增加三种已获批准或处于后期阶段的溶酶体储存疾病疗法。</p>
<p>根据协议条款，拜玛林将以现金支付爱美医疗所有股份，总对价为 48 亿美元。此交易将使拜玛林每股支付 14.50 美元，相当于爱美医疗 12 月 18 日收盘时 10.89 美元股价的 33% 溢价。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>免疫肿瘤学（IO）- 主题情报</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Amondys 45</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，接触到 36 个领先媒体平台上的专业人士。</p>
<p>了解更多</p>
<p>拜玛林的股价因收购而上涨 17.71%，从 12 月 18 日的 51.95 美元收盘上涨至 12 月 19 日的 61.15 美元。</p>
<p>这笔数十亿美元的交易是拜玛林历史上最大的一笔，将使制药公司获得爱美医疗的法布里病疗法 Galafold（migalastat）的权利，该药自 2018 年以来在美国市场上销售。2024 年，该药为爱美医疗带来了 4.581 亿美元的收入，比 2023 年增长了 18%。</p>
<p>Galafold 目前是美国食品和药物管理局（FDA）批准的唯一法布里病伴随治疗药物，这是一种罕见的遗传疾病，特征是患者细胞内脂肪基质的积累。</p>
<p>在与仿制药巨头 Teva Pharmaceuticals 的美国专利诉讼后，Galafold 现在拥有市场独占权，直到 2027 年 1 月 30 日。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>来自 GlobalData</p>
<p>了解更多关于战略情报</p>
<p>拜玛林还将获得爱美医疗 FDA 批准的庞贝病组合疗法 Pombiliti（cipaglucosidase alfa-atga）和 Opfolda（miglustat）的权利，该疗法于 2023 年获得 FDA 批准用于对标准酶替代疗法无反应的患者。该药在 2024 年产生了 2200 万美元的收入。</p>
<p>与法布里病类似，庞贝病是一种溶酶体储存疾病，阻碍糖原的代谢，导致其在细胞内的有害积累。这可能导致逐渐加重的肌肉无力和心脏问题。</p>
<p>除了这些已批准的疗法外，拜玛林还将获得晚期研究口服小分子 DMX-200 在罕见肾病焦点节段性肾小管硬化症（FSCS）中的美国权利，该药目前正在 进行 III 期临床试验。爱美医疗最初于 2025 年 5 月以高达 1.05 亿美元的价格从药物的创造者 Dimerix 手中购买了 DMX-200 的美国权利。</p>
<h2>拜玛林展望未来增长</h2>
<p>在过去几年中，拜玛林 一直在寻求进一步扩大其在制药行业的增长。</p>
<p>为实现这一目标，该公司在 2024 年进行了 重大重组，裁员 225 人。</p>
<p>进入 2025 年，拜玛林采取了强有力的交易策略，该公司在 2025 年签署了 10 项交易。根据 GlobalData 的制药情报中心，这是自 2010 年以来一年内签署的交易数量最多的一次。</p>
<p>其中一项较为显著的交易是拜玛林 收购 Inozyme，花费了 2.7 亿美元，同时将 Inozyme 的晚期酶替代疗法 INZ-701 纳入其产品线。</p>
<p>在与爱美医疗合并后，拜玛林指出，Galafold 和 Pombiliti-Opfolda 均具有 “高增长潜力”，这意味着此次收购可能进一步加速公司的收入增长。</p>
<p>这可能会得到 Galafold 和 Pombiliti-Opfolda 全球市场扩展的进一步支持，拜玛林在 12 月 19 日的声明中提到这是一个可能性。</p>
<p>GlobalData 的分析师，_Pharmaceutical Technology_的母公司，目前预测 Galafold 将在 2031 年产生 8.4 亿美元的销售额，而 Pombiliti-Opfolda 预计在同年带来 6.91 亿美元的收入。</p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p>提名现已结束，感谢所有参与的组织——你们的反应非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>卓越行动</strong></p>
<p>Upperton Pharma Solutions 因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖。Upperton 正在迅速扩大其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模式如何帮助制药公司从早期开发阶段顺利过渡到临床和小众商业供应，减少交接环节并加快时间进度。</p>
<p>发现影响</p>

爱美医疗

拜玛林制药

<p>拜玛林制药已同意以 48 亿美元收购爱美医疗，增强其罕见疾病产品组合。此次收购包括针对法布里病和庞贝病的疗法，以及一种晚期肾病治疗方案。拜玛林的股票在公告后上涨了 17.71%。这笔交易是拜玛林历史上最大的一笔，旨在扩大其在制药行业的布局，并预计从收购的疗法中实现显著的收入增长</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2213771699-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_2213771699-430x241.jpg"/></p>
<p>BioMarin Pharmaceutical has entered into a definitive agreement to acquire rare disease biotech, Amicus Therapeutics for $4.8bn. Image credit: T. Schneider via ShutterStock.com.</p>
<div class="lb-trans"><p>拜玛林制药已达成最终协议，以 48 亿美元收购罕见疾病生物技术公司爱美医疗。图片来源：T. Schneider via ShutterStock.com。</p>
</div><p>BioMarin Pharmaceutical has agreed to buy rare disease biotech Amicus Therapeutics, adding three approved or late-stage lysosomal storage disorder therapies to its portfolio.</p>
<div class="lb-trans"><p>拜玛林制药已同意收购罕见疾病生物技术公司爱美医疗，向其产品组合中增加三种已获批准或处于后期阶段的溶酶体储存疾病疗法。</p>
</div><p>Under the terms of the agreement, BioMarin will pay cash for all of Amicus’ shares for a total consideration of $4.8bn. This deal will set BioMarin back $14.50 per share, constituting a 33% premium on Amicus’ $10.89 18 December stock value at market close.</p>
<div class="lb-trans"><p>根据协议条款，拜玛林将以现金支付爱美医疗所有股份，总对价为 48 亿美元。此交易将使拜玛林每股支付 14.50 美元，相当于爱美医疗 12 月 18 日收盘时 10.89 美元股价的 33% 溢价。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Immuno-oncology (IO) - Thematic Intelligence</h4>
<div class="lb-trans"><h4>免疫肿瘤学（IO）- 主题情报</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Amondys 45</h4>
<div class="lb-trans"><h4>NPVM: Amondys 45</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，接触到 36 个领先媒体平台上的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>BioMarin’s stock has increased 17.71% on the acquisition, from an 18 December close of $51.95 to a 19 December close of $61.15.</p>
<div class="lb-trans"><p>拜玛林的股价因收购而上涨 17.71%，从 12 月 18 日的 51.95 美元收盘上涨至 12 月 19 日的 61.15 美元。</p>
</div><p>This multi-billion-dollar deal, which is the biggest in BioMarin’s history, will give the pharma rights to Amicus’ Fabry disease therapy, Galafold (migalastat), which has been on the US market since 2018. In 2024, the drug brought in $458.1m for Amicus, an 18% increase on 2023.</p>
<div class="lb-trans"><p>这笔数十亿美元的交易是拜玛林历史上最大的一笔，将使制药公司获得爱美医疗的法布里病疗法 Galafold（migalastat）的权利，该药自 2018 年以来在美国市场上销售。2024 年，该药为爱美医疗带来了 4.581 亿美元的收入，比 2023 年增长了 18%。</p>
</div><p>Galafold is currently the only US Food and Drug Administration (FDA) approved chaperone therapy for Fabry disease – a rare genetic disorder characterised by the buildup of fatty substrates in the cells of an affected patient.</p>
<div class="lb-trans"><p>Galafold 目前是美国食品和药物管理局（FDA）批准的唯一法布里病伴随治疗药物，这是一种罕见的遗传疾病，特征是患者细胞内脂肪基质的积累。</p>
</div><p>Following a US patent litigation with generics giant Teva Pharmaceuticals, Galafold now holds market exclusivity until January 30, 2027.</p>
<div class="lb-trans"><p>在与仿制药巨头 Teva Pharmaceuticals 的美国专利诉讼后，Galafold 现在拥有市场独占权，直到 2027 年 1 月 30 日。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>来自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>BioMarin will also acquire the rights to Amicus’ FDA-approved Pompe disease combination, Pombiliti (cipaglucosidase alfa-atga) plus Opfolda (miglustat), which got the FDA go-ahead for use in patients who are not responding to standard enzyme replacement therapy back in 2023. The drug generated $22m in 2024.</p>
<div class="lb-trans"><p>拜玛林还将获得爱美医疗 FDA 批准的庞贝病组合疗法 Pombiliti（cipaglucosidase alfa-atga）和 Opfolda（miglustat）的权利，该疗法于 2023 年获得 FDA 批准用于对标准酶替代疗法无反应的患者。该药在 2024 年产生了 2200 万美元的收入。</p>
</div><p>Like Fabre disease, Pompe disease is a lysosomal storage disorder that prevents the metabolism of glycogen, leading to its harmful buildup within the cells. This can lead to progressive muscular weakness and heart problems.</p>
<div class="lb-trans"><p>与法布里病类似，庞贝病是一种溶酶体储存疾病，阻碍糖原的代谢，导致其在细胞内的有害积累。这可能导致逐渐加重的肌肉无力和心脏问题。</p>
</div><p>Alongside these approved therapies, BioMarin will take ownership of the US rights to the late-stage, investigational oral small molecule, DMX-200, which is currently in Phase III trials for rare kidney disease, focal segmental glomerulosclerosis (FSCS). Amicus originally purchased the US rights to DMX-200 from the drug’s creator, Dimerix, for up to $105m in May 2025.</p>
<div class="lb-trans"><p>除了这些已批准的疗法外，拜玛林还将获得晚期研究口服小分子 DMX-200 在罕见肾病焦点节段性肾小管硬化症（FSCS）中的美国权利，该药目前正在 进行 III 期临床试验。爱美医疗最初于 2025 年 5 月以高达 1.05 亿美元的价格从药物的创造者 Dimerix 手中购买了 DMX-200 的美国权利。</p>
</div><h2>BioMarin eyes future growth</h2>
<div class="lb-trans"><h2>拜玛林展望未来增长</h2>
</div><p>Over the last couple of years, BioMarin has been looking to further its growth in the pharmaceutical sector.</p>
<div class="lb-trans"><p>在过去几年中，拜玛林 一直在寻求进一步扩大其在制药行业的增长。</p>
</div><p>In a bid to achieve this, the company underwent a significant restructuring in 2024, which saw it let go of 225 employees.</p>
<div class="lb-trans"><p>为实现这一目标，该公司在 2024 年进行了 重大重组，裁员 225 人。</p>
</div><p>Moving into 2025, BioMarin has employed a strong dealmaking strategy, which saw the company sign 10 deals in 2025. According to GlobalData’s Pharmaceutical Intelligence Center, this is the highest number of deals to be signed in one year since 2010.</p>
<div class="lb-trans"><p>进入 2025 年，拜玛林采取了强有力的交易策略，该公司在 2025 年签署了 10 项交易。根据 GlobalData 的制药情报中心，这是自 2010 年以来一年内签署的交易数量最多的一次。</p>
</div><p>One of the more prominent deals was BioMarin’s acquisition of Inozyme, which set it back $270m, while adding Inozyme’s late-stage enzyme replacement therapy, INZ-701, to its pipeline.</p>
<div class="lb-trans"><p>其中一项较为显著的交易是拜玛林 收购 Inozyme，花费了 2.7 亿美元，同时将 Inozyme 的晚期酶替代疗法 INZ-701 纳入其产品线。</p>
</div><p>Following its merger with Amicus, BioMarin noted that both Galafold and Pombiliti-Opfolda have “high growth potential,” meaning the acquisition could further accelerate the company’s revenue growth moving forward.</p>
<div class="lb-trans"><p>在与爱美医疗合并后，拜玛林指出，Galafold 和 Pombiliti-Opfolda 均具有 “高增长潜力”，这意味着此次收购可能进一步加速公司的收入增长。</p>
</div><p>This could be further supported by the expansion of Galafold and Pombiliit-Opfolda’s global footprint, which BioMarin mentioned as a possibility in a 19 December statement.</p>
<div class="lb-trans"><p>这可能会得到 Galafold 和 Pombiliti-Opfolda 全球市场扩展的进一步支持，拜玛林在 12 月 19 日的声明中提到这是一个可能性。</p>
</div><p>Analysts at GlobalData, parent company of <em>Pharmaceutical Technology</em>, currently forecast that Galafold will generate sales of $840m in 2031, while Pombiliti-Opfolda is expected to bring in $691m during the same year.</p>
<div class="lb-trans"><p>GlobalData 的分析师，_Pharmaceutical Technology_的母公司，目前预测 Galafold 将在 2031 年产生 8.4 亿美元的销售额，而 Pombiliti-Opfolda 预计在同年带来 6.91 亿美元的收入。</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>提名现已结束，感谢所有参与的组织——你们的反应非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>卓越行动</strong></p>
</div><p>Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.</p>
<div class="lb-trans"><p>Upperton Pharma Solutions 因在 综合制造 方面的业务扩展而获得 2025 年制药技术卓越奖。Upperton 正在迅速扩大其在英国的 GMP 和无菌制造能力。了解 Upperton 的综合 CDMO 模式如何帮助制药公司从早期开发阶段顺利过渡到临床和小众商业供应，减少交接环节并加快时间进度。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>发现影响</p>
</div>

拜玛林制药以 48 亿美元收购爱美医疗，旨在推动罕见病领域的发展